Midostaurin

Midostaurin, sold under the brand name Rydapt by Novartis, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Wikipedia contributors, "Midostaurin", Wikipedia, revision 1328964799, retrieved 20 November 2026, source, CC BY-SA 4.0.